At the IGTP TODAY

News

- Innovation, Research

Progress in developing specific immunotherapies for type 1 diabetes

Researchers from IGTP and Ahead Therapeutics have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of Autoimmunity examines the response of macrophages to this immunotherapy, serving as a preliminary step before clinical trials.

- Research

Type 1 diabetes research sheds light on biomarkers in partial remission phase

Researchers from the IGTP have led a comprehensive review study on biomarkers for the often-overlooked partial remission phase of type 1 diabetes, in collaboration with experts in β-cell biology and regeneration from the Diabetes Research Institute in Miami. The study has been published in the journal Trends in Endocrinology and Metabolism.

- Research

New biomarkers to monitor and predict the remission phase (honeymoon) in children with type 1 diabetes

A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Parc Tauli Hospital published in Frontiers in Immunology shows that a sample of peripheral blood can be used to identify levels of cells and molecules of the immune system that are specifically altered during the remission phase in paediatric type 1 diabetes (T1D). These can be used to monitor this phase and predict the progress of the disease.

- Research

A pilot study reveals that natural killer cells could track the progress of type 1 diabetes

The Immunology of Diabetes Group, led by Marta Vives-PI has shown that levels of 4 subtypes of natural killer (NK) cells in the blood of Type 1 Diabetes patients change through different stages of the disease. These cells have a complex role in the immune attack during T1D and have been implicated in both the destruction and protection of insulin-producing cells. This pilot study, published in Frontiers in Immunology, tracks the levels of 4 subtypes of NK cells and suggests that these cells are good candidate biomarkers for disease progression.